4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Biotechnology

Healthcare
$10.46 +1.70%

+$0.16 today

Market cap
$577.85M
Beta
2.76
P/E (TTM)
-4.0
EPS (TTM)
-$2.36
52W Low $3.68High $12.34

Volume 0.68M

Average 0.77M

FDMT Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

4D Molecular Therapeutics, Inc.NASDAQ: FDMT

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 68.06M shares rose 22.1% year over year, ahead of the +7.9% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 17.5% from the prior quarter. Over 3 fiscal years it compounded at +21.4% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +22.1% holds above the trailing-twelve-month pace of +7.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
68.06M+17.5% QoQ
Last fiscal yearDec 2025
57.93M+7.4% YoY
LTMMar 2026
59.51M+7.9% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+22.1%——
1 year+7.4%——
3-year CAGR+21.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
57.93M USD
Year-over-year change
+7.4%
4-year CAGR
+20.2%

Weighted Avg Shares (Diluted) vs competitors

How FDMT compares with its peers on the latest reported figures

  • FDMT's LTM Mar 2026 weighted avg shares (diluted) of 59.51M shares is the 6th highest of the 8 companies compared; the peer median is 65.52M shares.
  • Its year-over-year change of +7.9% is the 7th highest of 8, against a peer median of +17.2%.
  • Over three fiscal years its annual growth of +21.4% compares with a peer median of +21.2%.
FDMT Competitors Peer median
Weighted Avg Shares (Diluted) for FDMT and competitors
Company Period LTM YoY 3-year CAGR
OCGNOcugen, Inc.LTM Mar 2026307.2M +9.9%+11.8%
SLDBSolid Biosciences Inc.LTM Mar 202698.28M +94.3%+117.4%
MGTXMeiraGTx Holdings plcLTM Mar 202680.99M +13.7%+21.2%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 202665.52M +98.2%+28.7%
ABEOAbeona Therapeutics Inc.LTM Mar 202660.91M +28.1%+103.4%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 202659.51M +7.9%+21.4%
QUREuniQure N.V.LTM Mar 202658.39M +17.2%+7.2%
RGNXREGENXBIO Inc.LTM Mar 202651.84M +1.8%+6.1%
Peer median (excluding FDMT) 65.52M+17.2%+21.2%

Competitors are the stored peer set for FDMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.04M3.13M20.72M37K85.21M
Cost of Revenue61.36M80.25M97.1M141.3M7.63M
Gross Profit(43.32M)(77.12M)(76.37M)(141.26M)77.58M
Gross Margin-240.2%-2464.8%-368.5%-381789.2%91.1%
Research & Development61.36M80.25M97.1M141.3M195.7M
Selling, General & Admin28.01M32.91M36.49M46.58M49.06M
Operating Expenses28.01M32.91M36.49M46.58M237.13M
Depreciation & Amortization1.52M2.4M4.2M6.71M7.63M
EBITDA(69.79M)(105.09M)(96.63M)(154.16M)(132.48M)
EBITDA Margin-386.9%-3358.6%-466.3%-416656.8%-155.5%
Operating Income(71.33M)(110.03M)(112.87M)(187.84M)(159.55M)
Operating Margin-395.5%-3516.5%-544.6%-507678.4%-187.2%
Interest Income137K2.57M12.21M27.05M19.48M
Interest Expense00000
Other Income / Expenses16K2.54M12.03M26.97M19.44M
Income Before Tax(71.32M)(107.49M)(100.84M)(160.87M)(140.11M)
Pre-Tax Margin-395.4%-3435.4%-486.6%-434778.4%-164.4%
Income Tax Expense00000
Net Income(71.32M)(107.49M)(100.84M)(160.87M)(140.11M)
Net Margin-395.4%-3435.4%-486.6%-434778.4%-164.4%
EPS (Basic)(2.46)(3.12)(2.58)(2.98)(2.42)
EPS (Diluted)(2.46)(3.12)(2.58)(2.98)(2.42)
Weighted Avg Shares27.73M32.35M39.13M53.94M57.93M
Weighted Avg Shares (Diluted)27.73M32.35M39.13M53.94M57.93M

4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Intrinsic Alpha fair value

Locked

Current Price

$10.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.